Determinants of the response of human blood vessels to nitric oxide donors in vivo - PubMed (original) (raw)
Comparative Study
. 1999 Jun;289(3):1662-8.
Affiliations
- PMID: 10336566
Comparative Study
Determinants of the response of human blood vessels to nitric oxide donors in vivo
G Barba et al. J Pharmacol Exp Ther. 1999 Jun.
Abstract
The potency of the nitric oxide (NO) donors glyceryltrinitrate (GTN) and 3-morpholinosydnonimine was compared in human dorsal hand veins, the radial artery, and the forearm resistance vessels. NO donors were more potent in veins and the radial artery (vessels with minimal basal NO-mediated dilatation) than in the resistance vascular bed (where basal NO is a major determinant of vascular tone). In contrast, 8-bromoguanosine 3',5'-cyclic monophosphate (a cGMP mimetic) was approximately equipotent in resistance arteries and veins and was less potent in the radial artery. Inhibition of phosphodiesterase V with dipyridamole did not alter the arteriovenous profile of GTN. Increasing the local concentration of NO in veins (by infusing sodium nitroprusside) reduced their sensitivity to GTN but not to 8-bromoguanosine 3',5'-cyclic monophosphate. Conversely, reducing endogenous NO production in the resistance vasculature led to time-dependent increases in the response to GTN. These data suggest that soluble guanylate cyclase rather than cGMP-dependent protein kinase or phosphodiesterase V is the site in the second messenger pathway that determines the arteriovenous profile of NO donors. Moreover, the sensitivity of soluble guanylate cyclase to NO donors might be regulated by the ambient concentration of NO, with increased local NO down-regulating the dilator response to NO donors.
Similar articles
- Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery.
MacAllister RJ, Calver AL, Riezebos J, Collier J, Vallance P. MacAllister RJ, et al. J Pharmacol Exp Ther. 1995 Apr;273(1):154-60. J Pharmacol Exp Ther. 1995. PMID: 7714761 - Effects of nitric oxide donors and inhibitors of nitric oxide signalling on endothelin- and serotonin-induced contractions in human placental arteries.
Sand AE, Andersson E, Fried G. Sand AE, et al. Acta Physiol Scand. 2002 Mar;174(3):217-23. doi: 10.1046/j.1365-201x.2002.00939.x. Acta Physiol Scand. 2002. PMID: 11906320 - Enhancing vascular relaxing effects of nitric oxide-donor ruthenium complexes.
Paulo M, Banin TM, de Andrade FA, Bendhack LM. Paulo M, et al. Future Med Chem. 2014 May;6(7):825-38. doi: 10.4155/fmc.14.26. Future Med Chem. 2014. PMID: 24941875 Review. - Vascular nitric oxide resistance in type 2 diabetes.
Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Bahadoran Z, et al. Cell Death Dis. 2023 Jul 11;14(7):410. doi: 10.1038/s41419-023-05935-5. Cell Death Dis. 2023. PMID: 37433795 Free PMC article. Review.
Cited by
- Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo.
Madhani M, Okorie M, Hobbs AJ, MacAllister RJ. Madhani M, et al. Br J Pharmacol. 2006 Nov;149(6):797-801. doi: 10.1038/sj.bjp.0706920. Epub 2006 Oct 3. Br J Pharmacol. 2006. PMID: 17016498 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources